Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis Ag ADR (NY: NVS ) 115.02 -0.59 (-0.51%) Official Closing Price Updated: 4:10 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Novartis Ag ADR < Previous 1 2 3 4 5 6 7 8 9 ... 41 42 Next > The Importance of Managing Bad Cholesterol: What You Should Know September 27, 2024 (BPT) - Sponsored by Novartis Pharmaceuticals Corporation Via Brandpoint As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 From FN Media Group LLC Via GlobeNewswire Balancing Dividends and Fundamentals: The Case of NYSE:NVS. September 13, 2024 Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals. Via Chartmill NYSE:NVS: good value for what you're paying. September 03, 2024 Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents. Via Chartmill Embassy of Italy in Singapore Presents ‘Superstar’ Architect Michele De Lucchi for Singapore Design Week 2024 September 20, 2024 Via AB Newswire How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END Via FinancialNewsMedia Uncovering Dividend Opportunities with NYSE:NVS. August 23, 2024 Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS). Via Chartmill Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR. August 07, 2024 The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout? Via Chartmill How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 From FN Media Group LLC Via GlobeNewswire 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets September 18, 2024 Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years September 18, 2024 Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... Via Benzinga Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday September 11, 2024 Via Benzinga Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday September 11, 2024 Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts September 05, 2024 Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential. Via Benzinga S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday September 05, 2024 Via Benzinga Topics Stocks Exposures US Equities Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs September 03, 2024 Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... Via Benzinga Topics Economy Exposures Interest Rates Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study August 28, 2024 Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in... Via Benzinga Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation August 28, 2024 From Lindy Biosciences Via Business Wire Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats August 26, 2024 The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. Via Investor's Business Daily Exposures Product Safety Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal August 26, 2024 Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemicals used in PET scans to enhance its European presence and cancer imaging... Via Benzinga 2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200 August 18, 2024 These companies' growth paths should only be briefly interrupted by headwinds. Via The Motley Fool Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug August 13, 2024 Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore... Via Benzinga The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors August 12, 2024 Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and... Via Newsfile Exposures Product Safety BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model August 08, 2024 Via Investor Brand Network FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease August 08, 2024 Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.... Via Benzinga Exposures Product Safety Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs August 06, 2024 Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. Via Benzinga Topics Lawsuit Exposures Financial Legal < Previous 1 2 3 4 5 6 7 8 9 ... 41 42 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.